HiPSC-RPE cells
PreclinicalBiologic
HiPSC-RPE cells is one of 21 biologic programs targeting AMD - Age-Related Macular Degeneration. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Transplantation
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Atgam
NovartisPhase 3
Olumiant
Eli LillyPhase 3
Fludara
SanofiPhase 2
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Trexall
Jazz PharmaceuticalsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Alkeran
AApotex Inc.
Phase 2
Actemra
RochePhase 2
Keppra
UCBPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HiPSC-RPE cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details